ENDPOINTS

United Therapeutics pays $800M-plus to grab Arena’s PhIII PAH drug

7 years ago

Pharma

Partnered with Novartis, tiny Cadent jumps out of stealth with $40M round for its CNS pipeline

7 years ago

Financing

Startups

Pfizer loses key Lyrica patent battle in the UK; Kleo Pharma closes $21M Series B round

7 years ago

News Briefing

FDA presses its campaign against rogue regenerative med players, cites StemGenex for illegal sales

7 years ago

Pharma

Cell/Gene Tx

South Korean regulator suspends Samsung BioLogics' stock, citing accounting violations

7 years ago

R&D

Pharma

Roche wins speedy FDA review for Tecentriq; South Korean authorities to look into Samsung BioLogics accounting ...

7 years ago

News Briefing

AstraZeneca makes $1B-plus in cash-and-stock deal granting Sobi US rights to RSV drug Synagis

7 years ago

R&D

Concert’s initial alopecia data fall short against Pfizer, prompting investor blow back

7 years ago

R&D

Regenxbio scores $180M vector deal; Bristol-Myers expands agreement to test Opdivo with Infinity's IPI-549

7 years ago

News Briefing

Clearside Bio loses nearly half its value pre-market as lead eye drug fails pivotal test

7 years ago

R&D

Coherus looks to disrupt Amgen’s $4B Neulasta franchise as analysts look for a deep discount on its copycat price

7 years ago

Pharma

Omeicos scores $19.5M in Series C to take its omega-3 drug to the next round

7 years ago

Financing

Startups

Illumina forks out $1.2B to buy rival Pacific Biosciences, placing long and short-read DNA tech under the same roof

7 years ago

Pharma

Urovant's overactive bladder drug scores in mid-stage trial

7 years ago

R&D

Vertex wins third CF approval in Europe; ERS Genomics grants DefiniGEN access to CRISPR/Cas9 tech

7 years ago

News Briefing

GW's cannabis-derived drug Epidiolex finally launches in the US with an average list price of $32,500

7 years ago

Pharma

Tonix jumps on rejigged phase III for PTSD drug; MeiraGTx scores another NIH deal; OpGen, Qiagen join hands to detect ...

7 years ago

News Briefing

FDA staff suggests safety profile of Sage postpartum depression drug disqualifies it from at-home infusions

7 years ago

Pharma

Acadia says Nuplazid cleared main goal in depression study, but data appear mixed

7 years ago

R&D

Gene therapy developer Orchard prices IPO at $14 to raise $200M

7 years ago

Financing

Cell/Gene Tx

Arch Venture sets its sights on raising $600M for Fund X

7 years ago

Financing

Pharma

Terns scores $80M in Series B financing led by Vivo, OrbiMed

7 years ago

Financing

China

AstraZeneca hands over some rights to Nexium, Vimovo to Grünenthal as it plots turnaround

7 years ago

Pharma

TherapeuticsMD wins FDA nod for hormone therapy, capping off drugmaker's prolific year

7 years ago

Pharma

about the author

author articles

United Therapeutics pays $800M-plus to grab Arena’s PhIII PAH drug

Partnered with Novartis, tiny Cadent jumps out of stealth with $40M round for its CNS pipeline

Pfizer loses key Lyrica patent battle in the UK; Kleo Pharma closes $21M Series B round

FDA presses its campaign against rogue regenerative med players, cites StemGenex for illegal sales

South Korean regulator suspends Samsung BioLogics' stock, citing accounting violations

Roche wins speedy FDA review for Tecentriq; South Korean authorities to look into Samsung BioLogics accounting ...

AstraZeneca makes $1B-plus in cash-and-stock deal granting Sobi US rights to RSV drug Synagis

Concert’s initial alopecia data fall short against Pfizer, prompting investor blow back

Regenxbio scores $180M vector deal; Bristol-Myers expands agreement to test Opdivo with Infinity's IPI-549

Clearside Bio loses nearly half its value pre-market as lead eye drug fails pivotal test

Coherus looks to disrupt Amgen’s $4B Neulasta franchise as analysts look for a deep discount on its copycat price

Omeicos scores $19.5M in Series C to take its omega-3 drug to the next round

Illumina forks out $1.2B to buy rival Pacific Biosciences, placing long and short-read DNA tech under the same roof

Urovant's overactive bladder drug scores in mid-stage trial

Vertex wins third CF approval in Europe; ERS Genomics grants DefiniGEN access to CRISPR/Cas9 tech

GW's cannabis-derived drug Epidiolex finally launches in the US with an average list price of $32,500

Tonix jumps on rejigged phase III for PTSD drug; MeiraGTx scores another NIH deal; OpGen, Qiagen join hands to detect ...

FDA staff suggests safety profile of Sage postpartum depression drug disqualifies it from at-home infusions

Acadia says Nuplazid cleared main goal in depression study, but data appear mixed

Gene therapy developer Orchard prices IPO at $14 to raise $200M

Arch Venture sets its sights on raising $600M for Fund X

Terns scores $80M in Series B financing led by Vivo, OrbiMed

AstraZeneca hands over some rights to Nexium, Vimovo to Grünenthal as it plots turnaround

TherapeuticsMD wins FDA nod for hormone therapy, capping off drugmaker's prolific year